Search
Rapport Therapeutics Inc
RAPPAdd to Watchlist
39.390USD
-2.280-5.47%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.88BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
12
analysts
Buy
Current Rating
56.636
Target Price
+35.92%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Rapport Therapeutics Inc
RAPP
12
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
How have Rapport Therapeutics IncRAPP's recent earnings per share performed?
The market expectation was USD -0.42, while Rapport Therapeutics IncRAPP's earnings per share (EPS) for the previous quarter was USD -0.72. EPS for the next quarter is expected at USD -0.96.
What is the analyst rating for Rapport Therapeutics Inc?
Based on the ratings of Rapport Therapeutics Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.